Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.

ABSTRACT:

Background

Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses.

Objective

To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif^® Efficacy in Multiple Sclerosis) studies and their extensions.

Methods

Subgroups were based on the number of additional alemtuzumab courses received. Exclusion criteria: other disease-modifying therapy (DMT); <12-month follow-up after last alemtuzumab course.

Results

In the additional-courses groups, Courses 3 and 4 reduced annualized relapse rate (12 months before: 0.73 and 0.74, respectively; 12 months after: 0.07 and 0.08). For 36 months after Courses 3 and 4, 89% and 92% of patients we

SUBMITTER: Comi G 

PROVIDER: S-EPMC7720359 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature